Multifocal/multicentric breast cancer connected to a patient's risk of local recurrence

October 28, 2012

Not all women diagnosed with operable breast cancer present with a single tumor; some have multifocal disease appear in the breast, which means multiple tumors found in the same breast quadrant, while others have multicentric disease, where multiple tumors are found in separate breast quadrants. Multifocal or multicentric disease is not a standard indication to receive radiation after mastectomy. For patients who undergo lumpectomy, radiation dose and extent is not altered based on multifocal or multicentric disease compared to patients presenting with a single tumor.

Though previous researchers have analyzed data on patients with this type of , "there is not a strong consensus on whether or not having multifocal or multicentric breast cancer leads to higher recurrence rates," says Tiffany Tam, MD, an attending physician in the Radiation Department at Fox Chase Cancer Center, who will present new findings about this on October 30 at the American Society for Radiation Oncology's 54th Annual Meeting.

Tam led a team of Fox Chase physicians in a retrospective study designed to investigate for possible differences in outcomes. They found no statistically significant difference in overall survival or distant recurrence, where the cancer spreads to other organs or tissues. However, local recurrence—having cancer return to the same area from which it was surgically removed—occurred more than 2.5 times more often among patients with multifocal/multicentric disease, compared to patients with a single .

Tam and her colleagues analyzed the medical records of 112 women who were treated for multifocal or multicentric breast cancer at Fox Chase between 1983 and 2010. They compared outcomes data from those patients with data from 263 women treated for unifocal disease during the same period. Patients from the two groups were matched by age, gender, and stage at diagnosis. The researchers incorporated data on hormone-receptor status, type of surgery, age, grade, stage, and other therapies into their analyses. Males and patients with ductal carcinoma in situ (DCIS), inflammatory breast cancer, or metastatic disease were all excluded from the study.

Overall survival rates and rates of distant recurrence were roughly equal between both groups. When the researchers accounted for all the variables, they found that multifocal or multicentric breast cancer patients were diagnosed with local recurrences about 2.6 times as often as patients with unifocal disease.

Tam says she was motivated to do the study after treating patients diagnosed with multifocal or multicentric disease. "For those patients who do not have any other indications for post-mastectomy radiation, I wondered whether or not multifocal or multicentric disease should be considered in the decision to offer radiation," she says.

The new study won't change clinical practice guidelines, Tam says, but it suggests that the number of tumors found in the breast perhaps should be considered—along with other risk factors when considering radiation therapy.

"Even though this study suggests having multifocal or multicentric disease leads to increase local recurrence, we cannot draw definite conclusions, as this is just a single institutional small retrospective study. It's an additional factor that oncologists can consider," Tam adds. It's not clear whether or not patients with this type of disease have a more aggressive form of cancer or if they have some other risk factor that makes them more susceptible to developing multiple tumors.

Those patients may benefit from therapy following , for example, to reduce the likelihood of local recurrence, though larger studies are needed to weigh the possible benefits against possible harms.

Related Stories

Recommended for you

Team identifies a switch that may help target dormant cancer cells

September 26, 2017
A study by scientists at the University of Arizona and the University of Pittsburgh may hold the key to targeting dormant—or inactive —cancer cells, which are resistant to chemotherapy and other treatments. The results ...

Researchers discover how enzyme 'shape-shifts' in drug-resistant leukemia

September 26, 2017
St. Jude Children's Research Hospital structural biologists have deciphered how the structure of the enzyme called Abl regulates its activity, enabling the enzyme to switch itself on and off. Understanding Abl's regulation ...

Researchers identify gene variants linked to a high-risk children's cancer

September 25, 2017
Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery may assist doctors in better diagnosing ...

Prostaglandin E1 inhibits leukemia stem cells

September 25, 2017
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.

MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer

September 25, 2017
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing ...

Cancer vaccines need to target T cells that can persist in the long fight against cancer

September 25, 2017
Cancer vaccines may need to better target T cells that can hold up to the long fight against cancer, scientists report.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.